Apply to trial NCT05404906

A few quick questions so the study team can decide if you might be a fit.

RecruitingDrug trial

AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive consolidation.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening